229 related articles for article (PubMed ID: 36012442)
21. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
22. Modeling Duchenne Muscular Dystrophy Cardiomyopathy with Patients' Induced Pluripotent Stem-Cell-Derived Cardiomyocytes.
Eisen B; Binah O
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240001
[TBL] [Abstract][Full Text] [Related]
23. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
24. Functional correction of dystrophin actin binding domain mutations by genome editing.
Kyrychenko V; Kyrychenko S; Tiburcy M; Shelton JM; Long C; Schneider JW; Zimmermann WH; Bassel-Duby R; Olson EN
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931764
[TBL] [Abstract][Full Text] [Related]
25. Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment.
Andrysiak K; Machaj G; Priesmann D; Woźnicka O; Martyniak A; Ylla G; Krüger M; Pyza E; Potulska-Chromik A; Kostera-Pruszczyk A; Łoboda A; Stępniewski J; Dulak J
Cardiovasc Res; 2024 Feb; 120(1):69-81. PubMed ID: 38078368
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.
Li J; Wang K; Zhang Y; Qi T; Yuan J; Zhang L; Qiu H; Wang J; Yang HT; Dai Y; Song Y; Chang X
Circulation; 2021 Nov; 144(22):1760-1776. PubMed ID: 34698513
[TBL] [Abstract][Full Text] [Related]
27. Generation of Duchenne muscular dystrophy patient-specific induced pluripotent stem cell line lacking exons 45-50 of the dystrophin gene (IITi001-A).
Eisen B; Ben Jehuda R; Cuttitta AJ; Mekies LN; Reiter I; Ramchandren S; Arad M; Michele DE; Binah O
Stem Cell Res; 2018 May; 29():111-114. PubMed ID: 29653394
[TBL] [Abstract][Full Text] [Related]
28. Generation of two genomic-integration-free DMD iPSC lines with mutations affecting all dystrophin isoforms and potentially amenable to exon-skipping.
Ferrari G; Muntoni F; Tedesco FS
Stem Cell Res; 2020 Mar; 43():101688. PubMed ID: 32087527
[TBL] [Abstract][Full Text] [Related]
29. Production of Duchenne muscular dystrophy cellular model using CRISPR-Cas9 exon deletion strategy.
Alizadeh F; Abraghan YJ; Farrokhi S; Yousefi Y; Mirahmadi Y; Eslahi A; Mojarrad M
Mol Cell Biochem; 2024 May; 479(5):1027-1040. PubMed ID: 37289342
[TBL] [Abstract][Full Text] [Related]
30. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
Wang Q; Yin H; Camelliti P; Betts C; Moulton H; Lee H; Saleh AF; Gait MJ; Wood MJ
J Gene Med; 2010 Apr; 12(4):354-64. PubMed ID: 20235089
[TBL] [Abstract][Full Text] [Related]
31. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
32. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
[TBL] [Abstract][Full Text] [Related]
33. IPSC derived cardiac fibroblasts of DMD patients show compromised actin microfilaments, metabolic shift and pro-fibrotic phenotype.
Soussi S; Savchenko L; Rovina D; Iacovoni JS; Gottinger A; Vialettes M; Pioner JM; Farini A; Mallia S; Rabino M; Pompilio G; Parini A; Lairez O; Gowran A; Pizzinat N
Biol Direct; 2023 Jul; 18(1):41. PubMed ID: 37501163
[TBL] [Abstract][Full Text] [Related]
34. Generation and characterization of an induced pluripotent stem cell line (ZSYYDNi001-A) from a patient with Duchenne muscular dystrophy carrying exon 51 deletion in the DMD gene.
Wang L; Li H; Li Y; Xu M; Lin J; Liao Z; Pei Z; Zhang C
Stem Cell Res; 2021 Oct; 56():102553. PubMed ID: 34619646
[TBL] [Abstract][Full Text] [Related]
35. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
[TBL] [Abstract][Full Text] [Related]
36. New advancements in CRISPR based gene therapy of Duchenne muscular dystrophy.
Eslahi A; Alizadeh F; Avan A; Ferns GA; Moghbeli M; Reza Abbaszadegan M; Mojarrad M
Gene; 2023 May; 867():147358. PubMed ID: 36914142
[TBL] [Abstract][Full Text] [Related]
37. Large-scale genome editing based on high-capacity adenovectors and CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.
Tasca F; Brescia M; Wang Q; Liu J; Janssen JM; Szuhai K; Gonçalves MAFV
Nucleic Acids Res; 2022 Jul; 50(13):7761-7782. PubMed ID: 35776127
[TBL] [Abstract][Full Text] [Related]
38. Intronic Alternative Polyadenylation in the Middle of the
Rani AQM; Yamamoto T; Kawaguchi T; Maeta K; Awano H; Nishio H; Matsuo M
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443516
[TBL] [Abstract][Full Text] [Related]
39. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
40. Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy.
Young CS; Mokhonova E; Quinonez M; Pyle AD; Spencer MJ
J Neuromuscul Dis; 2017; 4(2):139-145. PubMed ID: 28505980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
